Download the white paper: A highly conserved neutralizing epitope on group 2 #Influenza A viruses by #Crucell

Don’t miss the opportunity to download the latest white paper by Robert Friesen, Vice President of Preclinical and Clinical Research at Crucell, which will share insights, strategies and challenges on novel development in immunotherapy and prophylaxis against Influenza A groups I and II at the European Antibody Congress 2011.

The identification and characterization of CR6261-like antibodies has already sparked considerable advances, including 1) their detection in some individuals and 2) design of immunization strategies that efficiently elicit stem antibodies in mice, ferrets, and monkeys (20, 25). Thus, the identification and characterization of CR8020 should facilitate similar advances for group 2 viruses, bringing us one step closer to the ultimate goal of a universal vaccine for influenza.

» Download the white paper: A highly conserved neutralizing epitope on group 2 Influenza A viruses